Palbociclib, Abemaciclib and Ribociclib all generated significant improvements in median progression free survival (PFS) when combined with an endocrine drug for the hormone receptor-positive advanced breast cancer patients9, 10. This evidence concerns the gene NR4A1 and breast carcinoma.